The stock of Qiagen NV (NASDAQ:QGEN) is a huge mover today! About 3.12M shares traded hands or 202.91% up from the average. Qiagen NV (NASDAQ:QGEN) has risen 4.22% since April 1, 2016 and is uptrending. It has outperformed by 3.01% the S&P500.
The move comes after 5 months positive chart setup for the $6.18B company. It was reported on Nov, 3 by Barchart.com. We have $38.92 PT which if reached, will make NASDAQ:QGEN worth $2.97 billion more.
Qiagen NV (NASDAQ:QGEN) Ratings Coverage
Out of 9 analysts covering Qiagen (NASDAQ:QGEN), 4 rate it a “Buy”, 0 “Sell”, while 5 “Hold”. This means 44% are positive. Qiagen has been the topic of 13 analyst reports since August 3, 2015 according to StockzIntelligence Inc. On Tuesday, March 15 the stock rating was maintained by Citigroup with “Neutral”. The rating was initiated by Morgan Stanley with “Overweight” on Tuesday, September 15. The stock of Qiagen NV (NASDAQ:QGEN) has “Hold” rating given on Thursday, November 12 by Stifel Nicolaus. The stock of Qiagen NV (NASDAQ:QGEN) has “Overweight” rating given on Thursday, July 30 by Barclays Capital. The firm earned “Neutral” rating on Thursday, July 30 by Mizuho.
According to Zacks Investment Research, “Qiagen NV produces biomedical and genetic products, products for separating and purifying nucleic acids for gene-based drug screening, nucleic acid-based clinical diagnostics, genetic vaccination and gene therapy.”
More important recent Qiagen NV (NASDAQ:QGEN) news were published by: Fool.com which released: “Qiagen NV Jumps After Beating Its Earnings Guidance” on November 03, 2016, also Rttnews.com published article titled: “Qiagen NV Announces 8% Rise In Q3 Profit”, Benzinga.com published: “Top Performing Industries For November 3, 2016” on November 03, 2016. More interesting news about Qiagen NV (NASDAQ:QGEN) was released by: Prnewswire.com and their article: “QIAGEN N.V. to Report Third Quarter and First Nine Months of 2016 Results” with publication date: October 11, 2016.
QGEN Company Profile
QIAGEN N.V. (QIAGEN), incorporated on April 29, 1996, is a holding company. The Firm and its subsidiaries are engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Sample to Insight solutions are composed of sample and assay technologies, bioinformatics and automation systems. The Company’s solutions support over 500,000 clients across the world in generating insights into the molecular building blocks of life. The Company’s over two billion biological samples have been prepared or analyzed using QIAGEN sample technologies. The Company’s sample technologies are used in isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. The Company’s assay technologies make these biomolecules visible for analysis, such as identifying the DNA of a virus or a gene mutation in a tumor. The Company’s bioinformatics solutions interpret data to provide actionable insights. The Company’s automation platforms tie these together in molecular testing workflows – from Sample to Insight. The Company’s Sample to Insight molecular technologies are applicable across a range of applications and customer classes through over 500 core consumable products, as well as instruments that automate the use of these products for sample preparation, analysis and interpretation. The Company’s bioinformatics solutions connect laboratory workflows and process amounts of genomic data, enabling scientists or clinicians to decide on further action. The Firm offers solutions in molecular diagnostics, applied testing, pharma and academia.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.